sur ARCHOS (EPA:ALJXR)
Successful capital increase at ARCHOS
The capital increase initiated by ARCHOS on April 9, 2024 was a great success with an oversubscription of 190.6%. This transaction marks the end of any dilutive financing for the company. The new capital now includes 58,053,021 shares, with a share held by management above 25%.
ARCHOS is now focusing on its 2024-2026 strategic plan, structured around three main markets: general public, professional and medical. The objective is to strengthen growth and profitability in the medium term, with ambitious forecasts of reaching €40M in turnover in 2024 and exceeding €50M in 2025.
The company also plans to launch new offers for Christmas 2024, including innovative solutions for the health and well-being of pets, and to increase its presence in the defense market. At the same time, ARCHOS is considering strategic partnerships in the health sector, such as with the startup DOMISANTE.
With a solid cash position of more than €10M, ARCHOS does not rule out the possibility of making targeted acquisitions to enrich its portfolio of high-tech solutions.
R. H.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ARCHOS